July 28, 2021 by Philips
Reading time: 1 minute
Patient deterioration is a significant clinical and financial burden for patients, providers, and healthcare systems.2 Clinicians are increasingly treating older, sicker populations at risk for complications and in-hospital adverse events.3 As the volume of hospitalizations for these patients continues to rise, providers are challenged to manage more acute, resource intensive populations in a resource-constrained environment.3 Compounded with a scarcity of beds in higher acuity care areas, patient status may be underestimated, and patients may be admitted or transferred to lower acuity care areas while still at risk for deterioration and resulting serious adverse events. This scenario may be attributable to a relative lack of resources in lower acuity settings, a significant decrease in nurse to patient ratios, and/or a lack of care coordination. However, evidence of the signs of patient deterioration may be present 6-24 hours prior to an event.5 For example, 66% of cardiac arrest patients show abnormal signs and symptoms up to 6 hours prior to cardiac arrest, but physicians are only notified 25% of the time.6 Moreover, nursing staff may be unaware of abnormal vital signs in almost 50% of patients in the general [i.e., lower acuity] ward7 as they struggle to manage time pressures and work interruptions throughout their shift.8
Patients experiencing adverse events are associated with higher direct healthcare costs.9 A review of the literature highlights this trend, especially among potentially preventable conditions:
DreamStation Go is a ultra portable positive airway pressure (PAP) therapy system designed for the frequent traveler. Patients can rely on its unique blend of connectivity, packability and powerful, convenient features.
Footnotes
You are about to visit a Philips global content page
ContinueThe information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).
By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.